SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...
VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...
BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...
Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...
Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio is an OTC nasal spray that is drug- and preservative-free and designed to provide triple protection against airborne viruses and allergens. First, it helps to protect the...
Closely-held PharmaJet was selected by partner, Scancell, to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, using the PharmaJet Tropis and PharmaJet Stratis Needle-free injection...
Michael Farber Closely-held RNA Disease Diagnostics appointed board-certified internist and professional sports physician, Michael Farber, M.D., to its advisory board. Dr. Farber is the medical director of executive...
Closely-held PharmaJet announced that its partner, Zydus Cadila, has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA vaccine for...
William Blair launched coverage of Icosavax (NASDAQ:ICVX) with an “outperform” rating. The stock closed at $34.09 on Aug. 20. “We believe Icosavax stands to benefit from both the medical and investment communities’...
BTIG initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $7. The stock closed at $2.80 on Aug. 6. CTI is a biotechnology company engaged in the development of therapeutics for blood...
Closely-held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. ...
Closely-held RNA Disease Diagnostics appointed Robert Ganz, a healthcare veteran with more than 40 years of executive experience in venture-backed startups and international healthcare companies, to the board. Mr. Ganz...
Lumos Diagnostics, with corporate head offices in Melbourne and U.S.-based R&D, commercial operations and manufacturing in both Florida and California, raised $63-million (Australian) in an initial public...
Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...
Paul LaBarre PharmaJet named Paul LaBarre as VP of global business development to lead business development and commercialization strategies, replacing Melissa Malhame, who transitioned to a strategic advisory role for...
The FDA registered the laboratory of Dipanjan Pan, Ph.D., at the University of Maryland School of Medicine, as an approved laboratory development site for RNA Disease Diagnostics’ (RNADD) Antisense COVID-19 molecular...
John Erickson Jr. RNA Disease Diagnostics (RNADD) appointed John Erickson, Jr. to the newly created position of president to lead day-to-day operations. He will report directly to company co-founder and executive...
Cantor Fitzgerald launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with an “overweight” rating and 12-month price target of $10. The stock closed at $2.66 on May 26. “We believe that the risk/reward profile is...
William Blair initiated coverage of Vaccitech plc (NASDAQ:VACC) with an “outperform” rating. The stock was quoted at $14.35 in afternoon trading on May 25. Vaccitech is a clinical-stage biotechnology company that...
SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...
Dawson James reduced its price target for Dyadic (NASDAQ:DYAI) to $6 from $12, citing uncertainty about the potential of its COVID-19 vaccine. The stock closed at $3.73 on May 14. “DYAI-100 (COVID) is advancing to human...
RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular...